- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06270706
Et fase 1-studie af PLN-101095 hos voksne med avancerede eller metastatiske solide tumorer
En fase 1a/1b multicenter, åben-label dosiseskalering/-udvidelsesundersøgelse til evaluering af sikkerhed, tolerabilitet, farmakokinetik og foreløbige beviser for antitumoraktivitet af PLN-101095 som monoterapi og i kombination med Pembrolizumab hos voksne deltagere med solid tumor eller metastasering Hvem har sygdomsprogression, mens de er på Pembrolizumab
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.
The study will consist of 2 main parts:
- Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
- Part 2: Dose-expansion cohorts using Simon's 2-stage design
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Pliant Therapeutics Medical Monitor
- Telefonnummer: clintrials@pliantrx.com
- E-mail: clintrials@pliantrx.com
Studiesteder
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06511
- Afsluttet
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Rekruttering
- Georgetown University Medical Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Winship Cancer Institute of Emory University
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49546
- Rekruttering
- South Texas Accelerated Research Therapeutics (START)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University Medicine
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
New Jersey
-
East Brunswick, New Jersey, Forenede Stater, 08816
- Rekruttering
- START New Jersey
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
New York
-
Lake Success, New York, Forenede Stater, 11042
- Rekruttering
- START New York Long Island LLC
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
North Carolina
-
Wilson, North Carolina, Forenede Stater, 27893
- Rekruttering
- Carolina Cancer Research Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Rekruttering
- Avera Medical Group
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Tennessee Oncology
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Texas
-
Austin, Texas, Forenede Stater, 78758
- Rekruttering
- NEXT Austin
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- START Center for Clinical Research
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- University of Texas MD Anderson Cancer Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Houston, Texas, Forenede Stater, 77054
- Rekruttering
- NEXT Houston
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- UT Health San Antonio's Mays Cancer Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Utah
-
West Valley City, Utah, Forenede Stater, 84119
- Rekruttering
- START Mountain Region
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Inova Schar Cancer Institute
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- NEXT Virginia
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Washington
-
Edmonds, Washington, Forenede Stater, 98026
- Rekruttering
- Swedish Cancer Institute Medical Oncology
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
-
-
Barcelona
-
Barcelona, Barcelona, Spanien, 08023
- Rekruttering
- Hospital Universitari Quirónsalud (NEXT Barcelona)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spanien, 08023
- Rekruttering
- START Barcelona - Hospital HM Nou Delfos
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron - VHIO
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
La Rioja
-
Logroño, La Rioja, Spanien, 26006
- Rekruttering
- START Center for Cancer Research - La Rioja
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Madrid
-
Madrid, Madrid, Spanien, 28040
- Rekruttering
- START Madrid - Hospital Universitario Fundación Jiménez Díaz
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Madrid, Madrid, Spanien, 28050
- Rekruttering
- START Madrid - Centro Integral Oncológico Clara Campal
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Pozuelo de Alarcón
-
Madrid, Pozuelo de Alarcón, Spanien, 28223
- Rekruttering
- University Hospital Quironsalud Madrid (NEXT Madrid)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Has histologically or cytologically confirmed advanced or metastatic solid tumor
- Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
- Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
- Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
- At least 1 measurable lesion, as defined by RECIST v1.1
- Estimated survival of ≥3 months
- Have adequate bone marrow and organ function.
- A female participant is eligible to participate if she is not pregnant, not breastfeeding
Exclusion Criteria:
- Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
- Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
- Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has known active CNS metastases (brain and/or leptomeningeal metastases)
- Has significant cardiac disease
- Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
- Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part 1 Dose Escalation - 250 mg BID
Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 1 Dose Escalation - 500 mg BID
PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 1 Dose Escalation - 1000 mg BID
PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 1 Dose Escalation - 1000 mg TID
PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 1 Dose Escalation - 2000 mg BID
PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 2 Dose Expansion - NSCLC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 2 Dose Expansion - ccRCC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 2 Dose Expansion - TMB-high solid tumors
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Tidsramme: First dose to 35 days
|
Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications. |
First dose to 35 days
|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Tidsramme: Day 1 until 16 weeks after end of study treatment regimen
|
Proportion of participants with treatment-emergent adverse events and serious adverse events. |
Day 1 until 16 weeks after end of study treatment regimen
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsramme: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsramme: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsramme: Day 14, 0 to up to 12 hours
|
Maximum drug concentration (Cmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsramme: Day 14, 0 to up to 12 hours
|
Time to Cmax (Tmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsramme: Day 14, 0 to up to 12 hours
|
Area under the concentration-time curve (AUC0-τ) |
Day 14, 0 to up to 12 hours
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsramme: First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
Duration of response (DOR) for objective responders |
First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsramme: First dose to progression or death from any cause, whichever occurs first
|
Time on treatment (TOT) for objective responders |
First dose to progression or death from any cause, whichever occurs first
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Pliant Therapeutics Medical Monitor, Pliant Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Urothelialt karcinom
- Immunterapi
- Pembrolizumab
- Melanom
- Kolorektal cancer
- Endometriecancer
- Ikke-småcellet lungekræft (NSCLC)
- Cholangiocarcinom
- Avanceret kræft i faste tumorer
- Galdeblære
- Ovariekarcinom
- Tredobbelt negativ brystkræft (TNBC)
- Anal karcinom
- Clear Cell Nyrecellekarcinom (CCRCC)
- Galdevejscarcinom (BTC)
- Hoved- og halskræft (HNSCC)
- Tumorer med høj tumor mutationsbyrde (TMB)
- TMB-lave tumorer
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Patologiske processer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Tarmsygdomme
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Lungesygdomme
- Neoplasmer i endokrine kirtler
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Tyktarmssygdomme
- Neoplastiske processer
- Lungeneoplasmer
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Hudsygdomme
- Brystsygdomme
- Urologiske neoplasmer
- Karcinom
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Nyre-neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Uterine neoplasmer
- Neuroendokrine tumorer
- Nevi og melanomer
- Neoplasmer i huden
- Brystneoplasmer
- Anus sygdomme
- Rektale neoplasmer
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Kolorektale neoplasmer
- Ovariale neoplasmer
- Neoplasma Metastase
- Karcinom, nyrecelle
- Karcinom, ikke-småcellet lunge
- Cholangiocarcinom
- Melanom
- Tredobbelt negative brystneoplasmer
- Endometriale neoplasmer
- Carcinom, overgangscelle
- Anus neoplasmer
- pembrolizumab
Andre undersøgelses-id-numre
- PLN-101095-ONC-101
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .